Literature DB >> 23886378

Prophylactic effect of monosodium glutamate on NSAID-induced enteropathy in rats.

Kikuko Amagase, Yuki Kimura, Akimitsu Wada, Tohru Yukishige, Toshiko Murakami, Eiji Nakamura, Koji Takeuchi1.   

Abstract

We reviewed the prophylactic effect of monosodium glutamate (MSG), a substance known as the "umami", on NSAID-induced small intestinal damage in rats. Loxoprofen, one of the NSAIDs frequently used in Asian countries, given orally at 60 mg/kg, caused hemorrhagic damage in the small intestine, mainly jejunum and ileum, concomitant with a down-regulation of Muc2 expression/ mucus secretion and an up-regulation of enterobacterial invasion and neutrophil migration as well as inducible nitric oxide synthase (iNOS) expression. The severity of these lesions was reduced by pretreatment with MSG (0.1~5%) given as a mixture of powder food (10 g/rat/day) for 5 days before administration of loxoprofen. The effect of MSG was accompanied by an up-regulation of Muc2 expression/ mucus secretion as well as a suppression of bacterial invasion, iNOS expression and myeloperoxidase activity. On the other hand, these lesions spontaneously healed within 7 days, but this process was hampered by loxoprofen at low doses (>10 mg/kg) given repeatedly for 5 days after ulceration. The healing-impairment effect of loxoprofen was accompanied by the down-regulation of vascular endothelium- derived growth factor (VEGF) expression and angiogenic response, and these responses were all antagonized by feeding diet containing 5% MSG for 5 days after ulceration. It is suggested that MSG exhibits a prophylactic effect against loxoprofen-induced small intestinal lesions, this effect is functionally associated with the up-regulation of Muc2 expression/mucus secretion, resulting in suppression of enterobacterial invasion and iNOS expression, the major pathogenic events in NSAID-induced enteropathy, and MSG also has the healing promoting effect on these lesions through enhancement of VEGF expression and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23886378     DOI: 10.2174/13816128113199990579

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

1.  Using human iPS cell-derived enterocytes as novel in vitro model for the evaluation of human intestinal mucosal damage.

Authors:  Satoshi Kondo; Shota Mizuno; Tadahiro Hashita; Takahiro Iwao; Tamihide Matsunaga
Journal:  Inflamm Res       Date:  2018-10-13       Impact factor: 4.575

Review 2.  Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment.

Authors:  Shuo Yuan; Qi Wang; Jiao Li; Jia-Chen Xue; You Li; Huan Meng; Xiao-Ting Hou; Ji-Xing Nan; Qing-Gao Zhang
Journal:  Chin Med       Date:  2022-06-18       Impact factor: 4.546

3.  Preparation and preliminary quality evaluation of aspirin/L-glutamate compound pellets.

Authors:  Mengchang Xu; Fenglin Liu; Wenhu Zhou; Binsheng He; Songwen Tan
Journal:  J Mater Sci Mater Med       Date:  2021-08-30       Impact factor: 3.896

Review 4.  Stem Cell-Based Therapies for Inflammatory Bowel Disease.

Authors:  Hua-Min Zhang; Shuo Yuan; Huan Meng; Xiao-Ting Hou; Jiao Li; Jia-Chen Xue; You Li; Qi Wang; Ji-Xing Nan; Xue-Jun Jin; Qing-Gao Zhang
Journal:  Int J Mol Sci       Date:  2022-07-31       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.